Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018

  • ID: 4518525
  • Drug Pipelines
  • 487 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • BioHealthonomics Inc
  • Gemac SA
  • Ionis Pharmaceuticals Inc
  • MimeTech Srl
  • Plex Pharmaceuticals Inc
  • MORE
Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate.

Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights:

This latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 24, 16, 2, 78, 21 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 34 and 9 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • BioHealthonomics Inc
  • Gemac SA
  • Ionis Pharmaceuticals Inc
  • MimeTech Srl
  • Plex Pharmaceuticals Inc
  • MORE
Introduction

Amyotrophic Lateral Sclerosis - Overview

Amyotrophic Lateral Sclerosis - Therapeutics Development

Amyotrophic Lateral Sclerosis - Therapeutics Assessment

Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development

Amyotrophic Lateral Sclerosis - Drug Profiles

Amyotrophic Lateral Sclerosis - Dormant Projects

Amyotrophic Lateral Sclerosis - Discontinued Products

Amyotrophic Lateral Sclerosis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Acceleron Pharma Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Apogenix AG, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Apotex Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Aquestive Therapeutics, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Avanir Pharmaceuticals Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by AveXis Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by BioElectron Technology Corp, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Biogen Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by BioHealthonomics Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by CerSci Therapeutics Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Corcept Therapeutics Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Corestem Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by CSPC NBP Pharmaceutical Co Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Denali Therapeutics Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Ensemble Therapeutics Corp, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Gemac SA, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Genentech Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex SA, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Gilead Sciences Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Glialogix Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Grifols SA, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Hemostemix Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Implicit Bioscience Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by InFlectis BioScience, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Italfarmaco SpA, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by K-Pax Pharmaceuticals Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by KineMed Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corp, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by M3 Biotechnology Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by MallInckrodt Plc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by MedDay SA, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by MimeTech Srl, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Miragen Therapeutics Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by Neurofx Inc, H1 2018

Amyotrophic Lateral Sclerosis - Pipeline by NeuroSense Therapeutics Ltd, H1 2018

List of Figures

Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • Acceleron Pharma Inc
  • Anavex Life Sciences Corp
  • Angion Biomedica Corp
  • Apogenix AG
  • Apotex Inc
  • Aquestive Therapeutics
  • ArmaGen Inc
  • Avanir Pharmaceuticals Inc
  • AveXis Inc
  • BioCrea GmbH
  • BioElectron Technology Corp
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioHealthonomics Inc
  • BrainStorm Cell Therapeutics Inc
  • Calico LLC
  • Catabasis Pharmaceuticals Inc
  • CerSci Therapeutics Inc
  • Chronos Therapeutics Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corcept Therapeutics Inc
  • Corestem Inc
  • CSPC NBP Pharmaceutical Co Ltd
  • Cytokinetics Inc
  • Daval International Ltd
  • Denali Therapeutics Inc
  • Eisai Co Ltd
  • Ensemble Therapeutics Corp
  • Evotec AG
  • Gemac SA
  • Genentech Inc
  • Genervon Biopharmaceuticals LLC
  • GeNeuro SA
  • GenKyoTex SA
  • Gilead Sciences Inc
  • Glialogix Inc
  • Grifols SA
  • Hemostemix Inc
  • Herantis Pharma Plc
  • Implicit Bioscience Ltd
  • InFlectis BioScience
  • Ionis Pharmaceuticals Inc
  • Italfarmaco SpA
  • Jeil Pharmaceutical Co Ltd
  • K-Pax Pharmaceuticals Inc
  • Kadimastem Ltd
  • KineMed Inc
  • Kringle Pharma Inc
  • Kyorin Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Lead Discovery Center GmbH
  • M's Science Corp
  • M3 Biotechnology Inc
  • Maas Biolab
  • MallInckrodt Plc
  • MedDay SA
  • MimeTech Srl
  • Miragen Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • Neuralstem Inc
  • Neuraltus Pharmaceuticals Inc
  • Neurimmune Holding AG
  • Neurofx Inc
  • NeuroSense Therapeutics Ltd
  • Neurotune AG
  • Orion Corporation
  • Orphazyme A/S
  • Pfizer Inc
  • Pharnext SA
  • Plex Pharmaceuticals Inc
  • Prevacus Inc
  • Priavoid GmbH
  • ProMIS Neurosciences Inc
  • Prosetta Biosciences Inc
  • Prothena Corp Plc
  • reMYND NV
  • SciFluor Life Sciences LLC
  • Teva Pharmaceutical Industries Ltd
  • TikoMed AB
  • Treeway BV
  • Valeant Pharmaceuticals International Inc
  • ViroMed Co Ltd
  • Voyager Therapeutics Inc
  • WAVE Life Sciences Ltd
  • Wilson Therapeutics AB
  • Yooyoung Pharm Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll